Navigation Links
OncoMed Pharmaceuticals Completes Series B Financing
Date:11/4/2008

Lead Cancer Stem Cell Product Candidate Enters Clinical Trials

REDWOOD CITY, Calif., Nov. 4 /PRNewswire/ -- OncoMed Pharmaceuticals, a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today announced the successful completion of the final tranche of its Series B financing round, raising $93 million. This tranche brings the total Series B financing to $154 million. New investor Nomura Phase4 Ventures participated in the financing along with existing OncoMed investors.

Proceeds from the financing will support the advancement of OncoMed's proprietary cancer stem cell antibody programs, including lead compound OMP- 21M18 and a second antibody, through Phase II clinical trials. OncoMed investors include top-tier venture capital firms US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Adams Street Partners, DeNovo Ventures and Bay Partners, as well as its strategic collaborator, GlaxoSmithKline.

"We are pleased to have completed this financing and to add Nomura Phase4 Ventures to our highly-regarded list of investors," said Paul Hastings, OncoMed's President and Chief Executive Officer. "These funds provide the company with multiple years of operating cash, and will enable OncoMed to take two cancer stem cell antibody therapeutics through Phase II clinical trials, as well as to expand our monoclonal antibody pipeline."

"Cancer stem cells appear to be a promising target for cancer treatment and OncoMed is a leader in the discovery of anti-cancer stem cell antibodies. We are pleased to support their development efforts through this investment," said Denise Pollard-Knight, Ph.D., Managing Director of Nomura Phase4 Ventures.

OMP-21M18 Enters Human Clinical Trials

OncoMed's lead anti-cancer stem cell antibody, OMP-21M18, entered human clinical studies earlier this year with the initiation of a Phase I trial in patients with advanced solid tum
'/>"/>

SOURCE OncoMed Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
2. Genesis Pharmaceuticals Launches New Corporate Website
3. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
4. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
5. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
6. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
7. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
9. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
11. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that Innovative ... e-Journal and producer of Food Labs Conference , ... the co-location of Food Labs Conference to be held in ... fee to attend the two-day Food Lab Conference, March 4-5. ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... has been created that contains antibodies against coccidiosis, a ... writing in the open access journal BMC Biotechnology ... demonstrate their effectiveness in preventing this economically important illness. ... from Novoplant GmbH, Germany, to develop the seeds. He ...
... In a development that holds much promise for the ... use of solar energy to produce clean and renewable ... Energy,s Lawrence Berkeley National Laboratory (Berkeley Lab) have reported ... crystals of the semiconductor cadmium-selenide was increased 100,000 times. ...
... OAKS, Calif., Sept. 11 Amgen (Nasdaq: AMGN ) ... Monday, Sept. 14, 2009, at the Grand Hyatt hotel in New ... CEO Kevin Sharer will present at the conference. Live audio of ... accessed from Amgen,s Web site, www.amgen.com, under Investors. , ...
Cached Biology Technology:Gold solution for enhancing nanocrystal electrical conductance 2Gold solution for enhancing nanocrystal electrical conductance 3Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:4/23/2014)... hungry diner ripping open a dinner roll, a fuel ... open a hydrogen molecule. Now researchers have captured a ... halves of its hydrogen feast. The view confirms previous ... catalyst work better for alternative energy uses. , This ... where the hydrogen halves end up in the structure ...
(Date:4/23/2014)... This news release is available in French ... , Montreal, 23 April 2014Today, the CEC released ... A Binational Collaborative Approach to Conservation, which identifies 29 ... States-Mexico border that includes 11 different protected areas in ... features unique, highly diverse arid and semi-arid habitats inhabited ...
(Date:4/23/2014)... A team of researchers in Korea ... the brains of nonhuman primates and assessed cell ... found that the hNSCs had differentiated into neurons ... , The study will be published in a ... is currently freely available on-line as an unedited ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... at the University of Southampton today, Monday 23 August, ... in Europe, Photon10, the latest developments in ,green photonics, ... technologies undertaken by the United States, Optoelectronics Development Association ... will help reduce CO 2 -creating energy consumption will ...
... Jodie Holt , a professor of plant physiology at ... James Cameron,s film Avatar , will receive ... work as a distinguished scientist and educator" at a ceremony ... Diego Botanic Garden, 230 Quail Gardens Drive, Encinitas, Calif. ...
... NY, August 20, 2010The U.S. needs a comprehensive and ... it remains competitive in the global science and technology ... latest issue of OMICS: A Journal of Integrative ... Liebert, Inc. ( www.liebertpub.com ). The commentary is available ...
Cached Biology News:$240 billion of green photonics by 2021 2A plan to promote sustainable US scientific discovery and innovation in the 21st century is proposed in OMICS 2
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
ANTI ALPHA FSH:B...
... Dog serum is collected from fasted mixed breed, ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
MOUSE ANTI BOVINE TROPONIN I...
Biology Products: